Trial Profile

An investigator sponsor clinical trial of Darovasertib in adjuvant uveal melanoma (UM)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Sep 2024 According to an IDEAYA Biosciences media release, the company announced successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant Uveal melanoma. Targeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDA.
23 Sep 2024 According to an IDEAYA Biosciences media release, the company announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma
13 May 2024 we are targeting to provide a clinical data update from our company-sponsored Phase 2 neoadjuvant UM trial and receive FDA regulatory guidance for a potential registrational path in the neoadjuvant uveal melanoma indication in the second half of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com